These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 18809598)

  • 1. Is fluorouracil-induced severe toxicity in DPYD*2A individuals related to sex or to treatment regimen?
    Deenen MJ; Beijnen JH; Schellens JH
    J Clin Oncol; 2008 Oct; 26(30):4997-8; author reply 4998-9. PubMed ID: 18809598
    [No Abstract]   [Full Text] [Related]  

  • 2. Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: a prospective clinical trial by the German 5-FU Toxicity Study Group.
    Schwab M; Zanger UM; Marx C; Schaeffeler E; Klein K; Dippon J; Kerb R; Blievernicht J; Fischer J; Hofmann U; Bokemeyer C; Eichelbaum M;
    J Clin Oncol; 2008 May; 26(13):2131-8. PubMed ID: 18299612
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil.
    van Kuilenburg AB
    Eur J Cancer; 2004 May; 40(7):939-50. PubMed ID: 15093568
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Severe or lethal toxicities upon capecitabine intake: is DPYD genetic polymorphism the ideal culprit?
    Mercier C; Ciccolini J
    Trends Pharmacol Sci; 2007 Dec; 28(12):597-8. PubMed ID: 18001850
    [No Abstract]   [Full Text] [Related]  

  • 5. Lack of large intragenic rearrangements in dihydropyrimidine dehydrogenase (DPYD) gene in fluoropyrimidine-treated patients with high-grade toxicity.
    Ticha I; Kleiblova P; Fidlerova J; Novotny J; Pohlreich P; Kleibl Z
    Cancer Chemother Pharmacol; 2009 Aug; 64(3):615-8. PubMed ID: 19288105
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predicting fluorouracil toxicity: can we finally do it?
    Ezzeldin HH; Diasio RB
    J Clin Oncol; 2008 May; 26(13):2080-2. PubMed ID: 18299611
    [No Abstract]   [Full Text] [Related]  

  • 7. 5-Fluorouracil-related severe toxicity: a comparison of different methods for the pretherapeutic detection of dihydropyrimidine dehydrogenase deficiency.
    Boisdron-Celle M; Remaud G; Traore S; Poirier AL; Gamelin L; Morel A; Gamelin E
    Cancer Lett; 2007 May; 249(2):271-82. PubMed ID: 17064846
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Two cases of 5-fluorouracil toxicity linked with gene variants in the DPYD gene.
    Ofverholm A; Arkblad E; Skrtic S; Albertsson P; Shubbar E; Enerbäck C
    Clin Biochem; 2010 Feb; 43(3):331-4. PubMed ID: 19822137
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Pharmacogenetics in oncology: 5-fluorouracil and the dihydropyrimidine dehydrogenase].
    Lazar A; Jetter A
    Dtsch Med Wochenschr; 2008 Jul; 133(28-29):1501-4. PubMed ID: 18597209
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hypermethylation of the DPYD promoter region is not a major predictor of severe toxicity in 5-fluorouracil based chemotherapy.
    Amstutz U; Farese S; Aebi S; Largiadèr CR
    J Exp Clin Cancer Res; 2008 Oct; 27(1):54. PubMed ID: 18937829
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of dihydropyrimidine dehydrogenase on 5-fluorouracil treatment in cancer patients.
    Schneider HB; Becker H
    Eur J Med Res; 2003 May; 8(5):226-8. PubMed ID: 12844478
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Standard fluoropyrimidine dosages in chemoradiation therapy result in an increased risk of severe toxicity in DPYD variant allele carriers.
    Lunenburg CATC; Henricks LM; Dreussi E; Peters FP; Fiocco M; Meulendijks D; Toffoli G; Guchelaar HJ; Swen JJ; Cecchin E; Schellens JHM; Gelderblom H
    Eur J Cancer; 2018 Nov; 104():210-218. PubMed ID: 30361102
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DPYD*2A and MTHFR C677T predict toxicity and efficacy, respectively, in patients on chemotherapy with 5-fluorouracil for colorectal cancer.
    Nahid NA; Apu MNH; Islam MR; Shabnaz S; Chowdhury SM; Ahmed MU; Nahar Z; Islam MS; Islam MS; Hasnat A
    Cancer Chemother Pharmacol; 2018 Jan; 81(1):119-129. PubMed ID: 29134491
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gender differences in the dihydropyrimidine dehydrogenase expression may contribute to higher toxicity in women treated with 5-fluorouracil therapy.
    Altundag O; Altundag K; Silay K; Turen S
    Med Hypotheses; 2005; 65(6):1196. PubMed ID: 15951130
    [No Abstract]   [Full Text] [Related]  

  • 15. DMET™ (Drug-Metabolizing Enzymes and Transporters) microarray analysis of colorectal cancer patients with severe 5-fluorouracil-induced toxicity.
    Rumiato E; Boldrin E; Amadori A; Saggioro D
    Cancer Chemother Pharmacol; 2013 Aug; 72(2):483-8. PubMed ID: 23760813
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 5-Fluorouracil toxicity-attributable IVS14 + 1G > A mutation of the dihydropyrimidine dehydrogenase gene in Polish colorectal cancer patients.
    Sulzyc-Bielicka V; Bińczak-Kuleta A; Pioch W; Kładny J; Gziut K; Bielicki D; Ciechanowicz A
    Pharmacol Rep; 2008; 60(2):238-42. PubMed ID: 18443386
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DPYD variants to predict 5-FU toxicity: the ultimate proof.
    Innocenti F
    J Natl Cancer Inst; 2014 Dec; 106(12):. PubMed ID: 25381394
    [No Abstract]   [Full Text] [Related]  

  • 18. The contribution of deleterious DPYD gene sequence variants to fluoropyrimidine toxicity in British cancer patients.
    Loganayagam A; Arenas-Hernandez M; Fairbanks L; Ross P; Sanderson JD; Marinaki AM
    Cancer Chemother Pharmacol; 2010 Jan; 65(2):403-6. PubMed ID: 19795123
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness and safety of reduced-dose fluoropyrimidine therapy in patients carrying the DPYD*2A variant: A matched pair analysis.
    Henricks LM; van Merendonk LN; Meulendijks D; Deenen MJ; Beijnen JH; de Boer A; Cats A; Schellens JHM
    Int J Cancer; 2019 May; 144(9):2347-2354. PubMed ID: 30485432
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Should DPD analysis be required prior to prescribing fluoropyrimidines?
    Yen JL; McLeod HL
    Eur J Cancer; 2007 Apr; 43(6):1011-6. PubMed ID: 17350823
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.